Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Comparative impact of tyrosine kinase inhibitor dose-reduction on ability to achieve treatment-free remission among TKI-intolerant patients with chronic myeloid leukemia

Melanie Rebechi, Nidhi Sharma, Audrey Propp et al. Nov 03, 2025 pp. 2004-2004 10.1182/blood-2025-2004

Abstract Background BCR-ABL1 tyrosine kinase inhibitors (TKIs) improve life expectancy to that of the general population...

Bystander activation drives CD8+ t cells response in lymphoma-associated hemophagocytic lymphohistiocytosis

Wendy Lee, Jing Quan Lim, Ser Mei Koh et al. Nov 03, 2025 pp. 4756-4756 10.1182/blood-2025-4756

Abstract Introduction Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory condition characterized by overt immune activation a...

Bgb-11417: A novel BCL2 inhibitor with robust antileukemic activity in T-cell acute lymphoblastic leukemia, alone or with vincristine

Hongfeng Pang, Chao-Ling Wan, Yuan-Hong Huang et al. Nov 03, 2025 pp. 6813-6813 10.1182/blood-2025-6813

Abstract T-cell acute lymphoblastic leukemia (T-ALL) is a malignant disorder characterized by the abnormal proliferation of immature T lymph...

PlatΤform: A multicenter, multi-arm, academic platform trial evaluating novel agents and combinations in relapsed or refractory peripheral T-cell lymphomas

David Sibon, Doriane Cavalieri, Mad-Helenie Elsensohn et al. Nov 03, 2025 pp. 3657-3657 10.1182/blood-2025-3657

Abstract Background: Peripheral T-cell lymphomas (PTCLs) are a heterogeneous and aggressive group of mature T- or NK-cell neoplasms, with poo...

7-day venetoclax combined with intensive chemotherapy as induction treatment in newly diagnosed Acute Myeloid Leukemia with splicing factor gene mutations

Congcong Zhang, Xiaohui SUO, Xingli Zhao et al. Nov 03, 2025 pp. 1618-1618 10.1182/blood-2025-1618

Abstract INTRODUCTION Mutations in splicing factor (SF) genes SRSF2, U2AF1, SF3B1, and ZRSR2 are now considered adverse risk in the European...

Comprehensive cost analysis of 4th line + therapies for relapsed/refractory multiple myeloma in Germany: Drug, co-medication, and office-based treatment perspective

Ulrike Sager, Stefan Norin, Bastian Hatesuer Nov 03, 2025 pp. 7918-7918 10.1182/blood-2025-7918

Abstract Introduction: The therapeutic landscape of RRMM is undergoing remarkable changes. In recent years, numerous innovative drugs have b...

Enhancing immunotherapy efficacy in myeloma with a novel dual-action mitochondrial toxic peptide that overcomes resistance and induces immunogenic cell death.

Smriti Gurung, Colin Crean, David Halladay et al. Nov 03, 2025 pp. 3924-3924 10.1182/blood-2025-3924

Abstract Background: T cell-engaging (TCE) immunotherapies have significantly improved outcomes in multiple myeloma (MM), but primary and acq...

Real-world analysis of asciminib as first-line therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A chart review Study in the United States

Ehab Atallah, Islam Mohamad Sadek, Emily McGovern et al. Nov 03, 2025 pp. 8178-8178 10.1182/blood-2025-8178

Abstract Introduction: Adenosine triphosphate (ATP)-competitivetyrosine kinase inhibitors (TKIs) are treatment options in newly diagnosed Ph...

Impact of ALK fusion variants and genetic profiles on prognosis in Chinese pediatric patients with ALK-positive anaplastic large cell lymphoma

Yang Li, Jing Yang, Yanlong Duan et al. Nov 03, 2025 pp. 3526-3526 10.1182/blood-2025-3526

Abstract Introduction: Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) is a major subtype of pediatric non-H...

Comprehensive analysis of subtype-specific outcomes and management in castleman disease: A 20-year cohort Study

Yoshito Nishimura, Brandon Brent, Kelley Dacus et al. Nov 03, 2025 pp. 3001-3001 10.1182/blood-2025-3001

Abstract Introduction: Castleman disease (CD) is a heterogeneous group of lymphoproliferative disorders classified anatomically as unicentri...

Survival prediction in relapsed/refractory B-cell lymphoma treated with CAR-T therapy: An AI-optimized cox regression model based on CCL5, scgf-β, and TRAIL

Hu Qian, Zekai Mao, Anqi Zhang et al. Nov 03, 2025 pp. 4115-4115 10.1182/blood-2025-4115

Abstract Objective: To identify prognostic biomarkers associated with long-term survival in patients receiving chimeric antigen receptor-T c...

MEFV E148Q-P369S-R408Q germ line variant identified from the adolescent imcd-tafro family conferred severe disease manifestations in a cohort of 37 patients with castleman disease

Yumo Du, Shuangfeng Xie, Zhen Dai et al. Nov 03, 2025 pp. 3007-3007 10.1182/blood-2025-3007

Abstract Background:Idiopathic multicentric Castleman disease with TAFRO (Thrombocytopenia, Anasarca, Fevers, Reticulin myelofibrosis, Organ...

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

Mattia D'Agostino, Esperanza Martin-Sanchez, David Zihala et al. Nov 03, 2025 pp. 364-364 10.1182/blood-2025-364

Abstract Background. CTCs are independent prognostic biomarkers in NDMM patients (pts) stratified by International Staging System (ISS) and...

Large language models mediated extraction of clinical information from bone marrow biopsy pathology reports

Luca Lanino, Theodore Getz, Tariq Kewan et al. Nov 03, 2025 pp. 2555-2555 10.1182/blood-2025-2555

Abstract Introduction: The promise of real-world data in advancing clinical research for patients with hematologic malignancies is often und...

Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey.

Fabio Stagno, Rosalba Cucci, Giovanni Marsili et al. Nov 03, 2025 pp. 3755-3755 10.1182/blood-2025-3755

Abstract Introduction: The BCR::ABL1 transcript is a defining characteristic of Chronic Myeloid Leukemia (CML) and European LeukemiaNet (ELN)...

BMS-986458, a first-in-class, highly selective, and potent ligand-directed degrader (LDD) of B-cell lymphoma 6 (BCL6) combined with T-cell engagers (TCEs) demonstrates preclinical synergistic antitumor efficacy for the treatment of B-cell non-Hodgkin lymphoma (NHL)

Gauri Deb, Alicia Benítez Rondán, Kelven Burnett et al. Nov 03, 2025 pp. 5090-5090 10.1182/blood-2025-5090

Abstract Introduction: BCL6 is a transcriptional repressor required for normal B-cell maturation. BCL6 is one of the most frequently genetic...

Azacitidine-associated cardiotoxicity: A systematic review of case reports, observational studies, and clinical trials

Ursula Medeiros Araujo de Matos, Rushali Manhas, Victoria Forbes Nov 03, 2025 pp. 6979-6979 10.1182/blood-2025-6979

Abstract Background: Azacitidine, a hypomethylating agent, is widely used in the treatment of myelodysplastic syndromes (MDS) and acute myel...

Real-world use of venetoclax and hypomethylating agents (HMA) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): A multi-institutional case series

Erica Lamkin, Shai Shimony, Shefali Mehra et al. Nov 03, 2025 pp. 6401-6401 10.1182/blood-2025-6401

Abstract Introduction: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic maligna...

Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory B-cell lymphomas: A systematic review and meta-analysis

Hanzala Jehangir, Sara Sharif, Muhammad Arham et al. Nov 03, 2025 pp. 1901-1901 10.1182/blood-2025-1901

Abstract Introduction: Relapsed or refractory B-cell lymphomas occur in approximately 30–40% of patients with large B-cell lymphoma, with ne...

Magnetic resonance imaging maps spatiotemporal changes in bone marrow composition of murine JAKV617F models of myelofibrosis during progression and therapy

Brian Ross, Christopher Bonham, Youngsoon Jang et al. Nov 03, 2025 pp. 2560-2560 10.1182/blood-2025-2560

Abstract Myeloproliferative neoplasms (MPN's) including myelofibrosis (MF) are neoplastic diseases that initiate in the bone marrow from abn...

Allogeneic hematopoietic stem cell transplantation in high-altitude hypoxia preserves graft-versus-leukemia without acute gvhd

Yigeng Cao, Xiaojing Ma, Erlie Jiang et al. Nov 03, 2025 pp. 7726-7726 10.1182/blood-2025-7726

Abstract Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for m...

The relationship between nutrition, hemoglobin, and frailty in elderly patients with Myelodysplastic Syndromes: A mediation effect analysis

Jinying Zhao, Zhongfan Kan, Qianqian Zhang et al. Nov 03, 2025 pp. 7399-7399 10.1182/blood-2025-7399

Abstract Objective The purpose of this study is to identify the hematological and non-hematological factors influencing frailty, to investig...

Medicaid versus commercial insurance: Association with quality of end-of-life care among patients with blood cancers

Hari Raman, Elizabeth Packnett, Edo Banach et al. Nov 03, 2025 pp. 285-285 10.1182/blood-2025-285

Abstract Introduction: Patients with blood cancers often receive suboptimal end-of-life (EOL) care, including high rates of healthcare utili...

A national analysis on ALK+ anaplastic large cell lymphomas: Community-based care linked to similar survival outcomes compared to academic centers.

Victor Mendiola, Leyla Bojanini, Erin Kaser et al. Nov 03, 2025 pp. 3642-3642 10.1182/blood-2025-3642

Abstract Background: Anaplastic large cell lymphomas (ALCLs) are malignancies of mature T lymphocytes, characterized by CD30 marker expressio...

Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis

Joshua Richter, Meral Beksac, Alessandro Corso et al. Nov 03, 2025 pp. 7567-7567 10.1182/blood-2025-7567

Abstract Introduction:The phase III DREAMM-8 study (NCT04484623) evaluated belantamab mafodotin, an antibody-drug conjugate targeting B-cell...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page